Unlock stock picks and a broker-level newsfeed that powers Wall Street.

IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

In This Article:

RESEARCH TRIANGLE PARK, N.C., April 23, 2025--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm Everest Group® has named IQVIA a "front-runner generative AI leader" for the life sciences industry in its recent report, "AI-deas to Action: Operationalizing Generative AI in Life Sciences."

IQVIA was the only clinical research organization to receive the highest ranking of front-runner in the report, which measures the value impact of end-to-end generative AI capabilities for 15 carefully selected broad-based AI companies, CROs and life sciences specialists and niche firms. IQVIA is also the only CRO with a dedicated technology business unit to receive this designation.

"By striving for operational excellence and emphasizing the need for responsible AI governance, IQVIA is taking a thoughtful approach to its generative AI strategy, scaling select use cases from concept to deployment to maximize value across the stages of the product life cycle," said Aastha Malik, practice director, Everest Group.

The report ranks IQVIA among five front-runners and says it showed industry leadership in its innovative strategic integrations of generative AI capabilities through various stages of research and development that help enable new ways of working. This includes several IQVIA Healthcare-grade AI® solutions to identify nuances in the patient journey for improved clinical trial design, enhanced product commercialization strategies with deeper provider engagement analytics and precise market access insights.

"Today’s life sciences and healthcare organizations are looking to balance AI innovation with continuous service delivery at high standards, striving for operational excellence," said Harietta Eleftherochorinou, vice president, AI Strategy and Operations, IQVIA. "The pace of AI advancement is extremely fast, making it important to implement AI with effective governance and drive tangible results while incentivizing for AI experimentation and keeping up to date with emerging AI technologies. With Healthcare-grade AI as our cornerstone for privacy, quality and trust, and building on the insights from over a decade of AI solutions in the market, we are systematic in identifying the areas where AI makes a real difference and moving effectively from AI ideas to operationalization to create real-world value for our customers and their patients."